Alex Goldberg

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) and Amazon.com Inc. (NASDAQ:AMZN) Added to Equity Profile Report's NASDAQ Decliners Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 02/05/2014 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) and Amazon.com Inc. (NASDAQ:AMZN).

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) a clinical stage biotechnology company that engages in the discovery and development of novel synthetic DNA- and RNA- based drug candidates is currently down (-8.45%) on 2,305,001 shares traded after Idera Pharmaceuticals Announced Public Offering of Common Stock and Pre-Funded Warrants. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) is currently down (-31.17%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Amazon.com Inc. (NASDAQ:AMZN) a company that operates as an online retailer in North America and internationally is currently down (-2.18%) on 1,579,523 shares traded after Amazon Publishing announced that Kindle Worlds has reached licensing agreements to open up seven new Worlds, including Worlds based on Hasbro’s iconic G.I. JOE brand, and Warner Bros. Amazon.com Inc. (NASDAQ:AMZN) is currently down (-17.22%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Amazon.com Inc. (NASDAQ:AMZN)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com